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Fig. S1. Levels of Z004 and Z021 human antibodies in mice and macaques. (A) Amount of 
human IgG antibodies in serum over time upon injection of 100µg of either Z004 or Z021 into 
FcγR/FcRn humanized mice. Four mice per group; shown is the mean ± SD. (B) Levels of 
human IgG antibodies in macaque plasma. The top panel displays human IgGs in individual 
macaques; the bottom panel shows the mean for each group. Macaques were administered 15 
mg/kg of each of the antibodies on day -1. The mean peak antibody levels on the day of infection 
(day 0) were 364 μg/ml in the Z004GRLR + Z021GRLR group and 289 μg/ml in the Z004GRLR/LS + 
Z021GRLR/LS group. The antibody levels on day 16 were 71 μg/ml in the Z004GRLR + Z021GRLR 
group and 85 μg/ml in the Z004GRLR/LS + Z021GRLR/LS group, resulting in plasma half-lives of 6.8 
and 9 days, respectively. Samples from macaques 6467 and 6476 (both treated with GRLR 
antibodies) were excluded from the calculation of the half-life since they were sampled on a 
different day. Control is plasma from a ZIKV infected, untreated animal. 
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Fig. S2. Administration of Z021 alone induces the emergence of resistant ZIKV in 
macaque. (A) Macaques were administered the Z021 monoclonal antibody 24 hours before 
intravenous inoculation with 105 PFU of Brazilian ZIKV. The top graph shows the measurement 
of plasma viremia over time upon Z021 treatment (blue), alongside the values previously 
reported for Z004 alone, Z004 + Z021, and untreated controls, for which the same virus, dose 
and route of administration were used (23). The bottom graph shows the time points analyzed 
that revealed T335 mutations in the virus EDIII region. (B) The epitope of ZIKV EDIII 
recognized by the Z021 antibody is shown in blue (PDB: 6DFI). The T335 residue is 
highlighted, as well as residues E393 and K394 that when mutated can confer resistance to Z004 
(23). (C) Z004 similarly neutralizes RVPs corresponding to wild type ZIKV sequence or ZIKV 
mutated at the T335 residue, while Z021 is less potent against viruses containing T335A or 
T335I. Data are represented as mean ± SD of triplicates and are relative to isotype control.  
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Fig. S3. Plasma antibody levels of Z004GRLR/LS + Z021GRLR/LS in dams and fetuses. (A) 
Levels of human IgG antibodies in plasma of pregnant macaques. The top panel displays human 
IgGs in individual macaques; the bottom panel shows the mean with standard deviation. 
Macaques were administered 15mg/kg of each of the antibodies 24 hours before each of the virus 
challenges, which occurred on GD30, GD60 and GD90. The mean peak antibody levels were 
526 μg/ml (GD30), 547 μg/ml (GD60) and 522 μg/ml (GD90); and the calculated half-lives were 
11.7 days (GD30-GD59), 12 days (GD60-GD89) and 9.6 days (GD90-GD104). In grey in the top 
panel are the values for the pregnancy that was prematurely terminated due to fetal loss, which 
did not receive a 2nd dose of antibodies, and which was excluded from the calculations for the 
average (bottom panel) and for the half-life values. (B) Human IgG levels in the dam and 
respective fetus (cord blood) at the time of euthanasia.  
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Fig. S4. Mutations in Zika virus emerge in plasma from antibody-treated pregnant 
macaques. On the left is a graphic summary of the identified mutations. Most of the mutations 
had already emerged in the antibody treated nonpregnant macaques (see Fig. 3). One exception 
was a virus detected in one animal with mutations resulting in 5 amino acid substitutions 
(L289W, T309I, V326I, M349V, H401Y); the effect of these mutations on antibody sensitivity 
could not be evaluated because we were unable to produce RVPs corresponding to these 
changes. We were unable to amplify the EDIII from most samples with RNA copies/ml below 
103. On the right, the mutations are mapped on the structure of the sE dimer of ZIKV (PDB ID: 
5JHM). The structures of the Z004-related antibody Z006 (PDB ID:5VIG) and of Z021 (PDB 
ID:6DFI) in complex with the EDIII of ZIKV are structurally aligned to the sE dimer to show the 
location of the mutated residues relative to the binding sites of the antibodies. Except for T309, 
all mutations are outside of the epitopes of both antibodies. The ZIKV EDIII from the Z006-
EDIII and Z021-EDIII structures are omitted for clarity. 
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Fig. S5. Detection of ZIKV RNA in amniotic fluid. Amniotic fluid was collected regularly by 
amniocentesis and tested for ZIKV RNA by qRT-PCR. Results are indicated as log10 ZIKV RNA 
copies/ml amniotic fluid, the mean of triplicate qRT-PCR replicates. Blank cells indicate samples 
that tested negative, i.e., below the limit of detection (~1.5 to 2.3 log10 ZIKV RNA copies/ml 
amniotic fluid, depending on volume). The intensity of red highlights the quantity of viral RNA 
detected. Cross-out indicates samples not tested, because either not collected (GD 37), not able 
to collect despite amniocentesis attempt, or early pregnancy termination; * indicates the 2 control 
animals and one antibody-treated animal with early fetal death. The ≥ GD 153 time point is the 
time of euthanasia. DPI: days post-infection; GD: gestational day. 
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Fig. S6. Fetal measurements at euthanasia from ZIKV infected macaques and from non-
infected historical controls. All measurements were collected on fetuses delivered via 
hysterotomy and immediately euthanized. The graphs include only fetuses that made it to the 
experimental endpoint (GD155-162) and exclude fetuses with early death. The historical controls 
are uninfected fetuses that also underwent intensive sampling as described earlier (11). (A) Fetal 
body and placental weights. (B) Fetal brain weights, including brain weight expressed as a 
percentage of total body weight. (C) Fetal organ weights. (D) Fetal bone measurements. (E) Age 
at conception and gestational day (GD) at time of euthanasia. (F) Sex of the fetuses.  
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Fig. S7. Fetal pathology scores. Fetal brain (13-20 sections per animal), placenta (1-2 sections 
per animal), amnion (1-2 sections per animal) and eye (2 sections per animal) were evaluated 
blindly by a pathologist and were assigned a score of 0 to 4 based on severity (Tables S2, S3 and 
(21)). Asterisks indicate animals with early fetal death, for which some tissues could not be 
evaluated due to autolysis. 
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Table S1. Histology of tissues from antibody treated dams.
Animal ID Spleen Mesenteric lymph node
Obturator lymph 
node Inguinal lymph node Uterus
AB01 Moderate lymphoid hyperplasia
Mild lymphoid 
hyperplasia
Moderate 
hemorrhage in 
sinuses
Moderate lymphoid 
hyperplasia
Small numbers of perivascular lymphocytes in 
endometrium and myometrium (WNL)
AB02 Mild lymphoid hyperplasia
Mild lymphoid 
hyperplasia N/A N/A
Small numbers of perivascular lymphocytes in the 
myometrium (WNL)
AB03 Mild lymphoid hyperplasia
Severe lymphoid 
hyperplasia WNL
Mild lymphoid 
hyperplasia
Small numbers of perivascular lymphocytes in 
endometrium and myometrium (WNL)
AB04 Mild lymphoid hyperplasia
Mild lymphoid 
hyperplasia
Moderate 
macrophages in 
sinuses with 
hemosiderin
Moderate hemorrhage 
in sinuses; mild 
lymphoid hyperplasia
Thick decidua with hemosiderin-laden macrophages; 
mild to moderate numbers perivascular lymphocytes in 
endometrium and myometrium
AB05 Moderate lymphoid hyperplasia
Mild lymphoid 
hyperplasia
Moderate 
hemorrhage in 
sinuses
Moderate hemorrhage 
in sinuses
Small numbers of perivascular lymphocytes in 
endometrium (WNL)
AB06 Moderate lymphoid hyperplasia
Mild lymphoid 
hyperplasia
Moderate 
macrophages in 
sinuses
Mild lymphoid 
hyperplasia
Small numbers of perivascular lymphocytes in 
endometrium (WNL)
AB07 Mild lymphoid hyperplasia
Moderate lymphoid 
hyperplasia WNL
Mild lymphoid 
hyperplasia
Small numbers of perivascular lymphocytes in 
endometrium and myometrium (WNL)
AB08 Mild lymphoid hyperplasia WNL WNL WNL
Small numbers of perivascular lymphocytes in 
endometrium and myometrium (WNL)
See in Van Rompay et al (ref. 21) for control pregnant macaques C01-C12; N/A is 'not available' and WNL is 'within normal limits'
Table S2. Histology of fetal tissues from antibody treatment group.
Fetus ID Central nervous system Eye Placenta Amnion Umbilical cord
Mesenteric lymph 
node Lung Liver Kidney Ileum
AB01-F
19 sections: B5, B6, 
B7: segmental 
attenuation/loss of 
ependyma, mild, 
with gliosis
WNL
Basal plate and 
decidua have mild 
multifocal 
neutrophilic 
vasculitis and few 
interstitial 
neutrophils
WNL WNL WNL
Multifocal mild 
congestion and 
hemorrhage; rare 
squames
Mild EMH; mild 
glycogen; no GB WNL WNL
AB02-F Severe autolysis Severe autolysis
Placental 
separation; 
hemorrhage, fibrin 
and necrosis within 
decidua
WNL N/A N/A Severe autolysis Severe autolysis N/A N/A
AB03-F
17 sections: B2: 
single focus 
mineral near 
ventricle
WNL
Basal plate and 
villous parenchyma 
multifocal areas of 
necrosis with 
neutrophils (slide 3-
1, not the best sxn)
Very small numbers 
of neutrophils within 
the stroma
WNL WNL Rare squames
Rare EMH; 
moderate glycogen; 
no GB
WNL WNL
AB04-F
17 sections: B2, B3: 
rare individual cells 
in ventricular 
lumen; B4, B5: 
segmental 
attenuation/loss of 
ependyma, mild, 
with gliosis; cystic 
choroid plexus
WNL Increased syncytial knots
Cystic change to 
epithelium; 
hemorrhage and 
hemosiderin-laden 
macrophages in 
stroma; thick decidua
WNL WNL Mild squames Moderate EMH; moderate glycogen WNL WNL
AB05-F
17 sections: B5: 
single focus 
mineral near 
ventricle
WNL WNL WNL WNL WNL Rare squames Mild EMH; moderate glycogen WNL WNL
AB06-F 19 sections: B6: LGN less layering WNL
Multifocal 
necrosis/loss of 
trophoblasts with 
neutrophils along 
fetal plate; large 
mid-disc infarct 
extending from the 
basal plate into the 
villous parenchyma 
with 
necrosis/mineraliza
tion of the basal 
plate and decidua; 
increased syncytial 
knots
Single area of 
moderate numbers of 
neutrophils within 
decidua
WNL WNL Mild squames Rare EMH; moderate glycogen WNL WNL
AB07-F
20 sections: 
Parietal lobe (10): 
multifocal 
mineralization near 
ventricle and 
adjacent neuronal 
rests; B2,B3: single 
rest mineralization
WNL
Severe decidual 
thickening with 
hemorrhage, 
edema and 
necrosis; multifocal 
ischemic necrosis 
of placenta full 
thickness (chronic 
and acute); mild 
lymphocytes and 
moderate 
neutrophils in 
decidua
Severe decidual 
thickening with 
multifocal small areas 
of hemorrhage and 
fibrin; mild 
lymphocytes
WNL N/A
Moderate 
hemorrhage within 
alveoli
Mild EMH; 
moderate glycogen WNL
Moderate 
hemorrhage within 
lumen; cytoplasmic 
protein droplets in 
enterocytes
AB08-F
19 sections: 
Parietal lobe (10), 
lateral ventricle 
(15), B3, B4, B5: 
single to few 
focus/foci 
periventricular 
mineralization; Lat 
ventricle (15), B4: 
mild loss of 
ependyma with 
gliosis; B6, B7: 
moderate 
ependymal loss
WNL
Fetal plate 
multifocal 
trophoblast 
necrosis with fibrin 
and neutrophils, 
multifocal very mild 
neutrophils in fetal 
vessels; decidua 
multifocal necrosis 
with neutrophils
WNL WNL WNL Moderate squames Rare EMH; mild glycogen WNL WNL
See in Van Rompay et al (ref. 21) for control pregnant macaques C01-C12; N/A is 'not available', WNL is 'within normal limits' and EMH is extra-medullary hematopoiesis
Table S3. Fetal pathology scoring. 
 
Score Placenta/fetal membranes Fetal neuropathology 
0 none - no lesions observed none - no lesions observed 
1 minimal - focal, small lesion in section, not 
observed in control animals but significance 
questionable, could be background lesion 
minimal - focal, small lesion in one brain 
section, not observed in control animals but 
significance questionable, could be 
background lesion 
2 mild – mild, multifocal lesions in section, 
single layer 
mild – mild ependymal loss in multiple brain 
sections +/- very few mineral foci 
3 moderate – mild to moderate lesions 
extensively throughout section, multiple 
layers 
moderate – mild to moderate ependymal loss 
in multiple sections, mineralization +/- 
cuffing 
4 severe – widespread lesions throughout 
section, multiple layers 
severe – widespread lesions in multiple brain 
sections 
 
Table S4. Macaques used in the study.
Animal ID Treatment Date of birth Sex Total prior pregnancies
Delivery of 
live infants
Age at necropsy 
(in years)
6467 Z004+Z021 GRLR 5/2/15 M n.a. n.a. 2.8
6476 Z004+Z021 GRLR 5/11/15 M n.a. n.a. 2.8
6408 Z004+Z021 GRLR 3/7/15 M n.a. n.a. 3.3
6425 Z004+Z021 GRLR 3/30/15 M n.a. n.a. 3.2
6430 Z004+Z021 GRLR 4/3/15 M n.a. n.a. 3.2
6446 Z004+Z021 GRLR 4/17/15 M n.a. n.a. 3.2
6543 Z004+Z021 GRLR/LS 4/21/16 F n.a. n.a. 2.8
6575 Z004+Z021 GRLR/LS 7/2/16 F n.a. n.a. 2.6
6522 Z004+Z021 GRLR/LS 3/19/16 F n.a. n.a. 2.9
6525 Z004+Z021 GRLR/LS 4/1/16 F n.a. n.a. 2.8
6553 Z004+Z021 GRLR/LS 5/6/16 F n.a. n.a. 2.7
6642 Z004+Z021 GRLR/LS 4/27/17 M n.a. n.a. 1.8
6496 untreated control 6/11/15 M n.a. n.a. 3.0
6315 untreated control 4/7/14 M n.a. n.a. 4.0
6500 untreated control 6/18/15 M n.a. n.a. 2.8
6501 untreated control 6/21/15 M n.a. n.a. 3.0
AB01 Z004+Z021 GRLR/LS 3/19/04 F 10 9 15.3
AB02 Z004+Z021 GRLR/LS 2/21/04 F 8 7 15.1
AB03 Z004+Z021 GRLR/LS 4/28/08 F 6 5 11.1
AB04 Z004+Z021 GRLR/LS 3/25/10 F 4 2 9.3
AB05 Z004+Z021 GRLR/LS 3/15/06 F 6 3 13.3
AB06 Z004+Z021 GRLR/LS 4/21/07 F 4 3 12.1
AB07 Z004+Z021 GRLR/LS 4/3/10 F 3 0 (1 abortion, 2 experimental harvests) 9.3
AB08 Z004+Z021 GRLR/LS 5/1/11 F 2 2 8.2
See in Van Rompay et al. (ref. 21) for control pregnant macaques C01-C12; n.a. is 'not applicable'.
LOW DOSE SUBCUTANEOUS ZIKV CHALLENGE (NONPREGNANT)
LOW DOSE SUBCUTANEOUS ZIKV CHALLENGE (PREGNANT)
Table S5. List of primers used in this study. 
 
Primer ID Primer sequence Comments 
Generation of pZIKV/HPF/CprM*PRVABC59E* 
RU-O-24379 ACTTGGTCATGATACTGCTGATTGCCCCGGCATACAGCAT
CAGGTGCATAGGAGT 
Forward with BspHI 
RU-O-24380 TTCGAACCGCGGCTGGGTCCTATTAAGCAGAGACAGCTG
TGGATAAGAAGATC 
Reverse with SacII 
Mutagenesis of pZIKV/HPF/CprM*PRVABC59E* to produce mutant ZIKV RVPs 
DFRp1477 ACTTGGTCATGATACTGCTGATTG Forward outer with BspHI 
DFRp1584 AACCGCGGCTGGGTCCTATTAAGCAGA Reverse outer with SacII 
DFRp1505 GACAGTCACAGTGGAGTTACAGTACGCAGGGAC Forward V330L 
DFRp1506 GTCCCTGCGTACTGTAACTCCACTGTGACTGTC Reverse V330L 
DFRp1503 GTGTCATACTCCTTGTGTGCTGCAGCGTTCACA Forward T309A 
DFRp1504 TGTGAACGCTGCAGCACACAAGGAGTATGACAC Reverse T309A 
DFRp1557 GTGTCATACTCCTTGTGTATTGCAGCGTTCACA Forward T309I 
DFRp1558 TGTGAACGCTGCAATACACAAGGAGTATGACAC Reverse T309I 
Mutagenesis of pZIKV/HPF/CprM*E* to produce mutant ZIKV RVPs 
DFRp1477 ACTTGGTCATGATACTGCTGATTG Forward outer with BspHI 
DFRp1481 CGAACCGCGGGCCCTCTAGATCAA Reverse outer with SacII 
DFRp1546 GCAGGGGCAGATGGACCTTGC Forward T335A 
DFRp1547 GCAAGGTCCATCTGCCCCTGC Reverse T335A 
DFRp1548 GCAGGGATAGATGGACCTTGC Forward T335I 
DFRp1549 GCAAGGTCCATCTATCCCTGC Reverse T335I 
 
